Evotec Nets $10M Milestone as Phase 1 Trial of BMS-986506 Launches
Evotec will receive a $10 million milestone payment after Bristol Myers Squibb initiated Phase 1 clinical dosing of BMS-986506, a CELMoD agent targeting advanced clear cell renal cell carcinoma. This study progression underscores Evotec’s high-performance PanOmics and AI-driven drug discovery platforms advancing novel molecular glue candidates into clinical development.
1. Clinical Trial Initiation
Evotec and Bristol Myers Squibb have initiated dosing of the first patient in the Phase 1 clinical evaluation of BMS-986506, a cereblon E3 ligase modulator targeting advanced clear cell renal cell carcinoma. This marks the first human study for the CELMoD candidate in Evotec’s oncology pipeline.
2. Milestone Payment Impact
Evotec secured a $10 million milestone payment upon clinical study initiation, reflecting progress in the strategic protein degradation collaboration. The payment boosts Evotec’s near-term cash flow and validates the partnership’s value-generating potential.
3. Integrated Discovery Platforms
The collaboration leverages Evotec’s integrated PanOmics screening and AI-powered PanHunter analytics platforms to identify and optimize molecular glue degraders. These technologies enable selective targeting and degradation of disease-driving proteins, expanding therapeutic options beyond conventional small molecule approaches.
4. Collaboration Pipeline Outlook
Initiated in 2018 and expanded in 2022, the Evotec-BMS collaboration aims to develop a pipeline of high-value molecular glue candidates across oncology and other indications. The Phase 1 launch of BMS-986506 paves the way for further clinical milestones and potential follow-on payments.